{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T02:31:38Z","timestamp":1776479498868,"version":"3.51.2"},"reference-count":11,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T00:00:00Z","timestamp":1500940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2017,10]]},"abstract":"Abstract<\/jats:title>\n \n Objective<\/jats:title>\n \n To evaluate the efficacy and safety of direct oral anticoagulant (\n DOAC<\/jats:styled-content>\n ) therapy in hospitalized patients with suspected heparin\u2010induced thrombocytopenia (\n HIT<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Retrospective cohort study of adult patients prescribed apixaban, dabigatran, or rivaroxaban for the treatment of acute\n HIT<\/jats:styled-content>\n from January 1, 2013 to January 1, 2017. Eligibility requirements included an intermediate or high pretest probability for\n HIT<\/jats:styled-content>\n (4T score\u22654) and a positive IgG\u2010specific anti\u2010\n PF<\/jats:styled-content>\n 4\/heparin complex assay. The primary outcome measure was the composite of newly diagnosed venous or arterial thromboembolism, gangrene, or amputation due to critical limb ischemia during hospitalization.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 12 patients were included for analysis, five of which experienced\n HIT<\/jats:styled-content>\n \u2010related thrombosis prior to initiation of\n DOAC<\/jats:styled-content>\n therapy. Seven patients received parenteral therapy with argatroban prior to initiation of\n DOAC<\/jats:styled-content>\n treatment. Nine patients were treated with apixaban while three received rivaroxaban for an average of 9.33\u00a0days while hospitalized. Zero patients experienced the primary outcome of\n HIT<\/jats:styled-content>\n \u2010related thrombosis, and no patients experienced major bleeding post\n DOAC<\/jats:styled-content>\n initiation. All patients achieved platelet recovery while receiving\n DOAC<\/jats:styled-content>\n therapy.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n In this small retrospective study of adult patients treated for acute\n HIT<\/jats:styled-content>\n , treatment with\n DOAC<\/jats:styled-content>\n therapy was not associated with in\u2010hospital thrombotic or hemorrhagic events.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/ejh.12921","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T15:12:41Z","timestamp":1499094761000},"page":"332-335","source":"Crossref","is-referenced-by-count":42,"title":["Direct acting oral anticoagulants for the treatment of suspected heparin\u2010induced thrombocytopenia"],"prefix":"10.1111","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-575X","authenticated-orcid":false,"given":"Kyle A.","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Pharmacy Wake Forest Baptist Medical Center Winston\u2010Salem NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne O.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Wake Forest Baptist Medical Center Winston\u2010Salem NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,25]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-709873"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-016-1365-0"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2303"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/107602960501100306"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23248"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2015.01.009"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-016-1420-x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13330"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12921","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T04:14:16Z","timestamp":1695528856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,25]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1111\/ejh.12921"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12921","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727779026.793541350","asserted-by":"object"}]},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,25]]}}}